LE, W., JT, L., AT, T., CJ, C., BE, Y., B, W., . . . KB, T. (2025). Nirmatrelvir/ritonavir treatment and risk for post-acute sequelae of COVID-19 in older Singaporeans: Author's response. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 31(1), 139. https://doi.org/10.1016/j.cmi.2024.10.002
Chicago Style (17th ed.) CitationLE, Wee, et al. "Nirmatrelvir/ritonavir Treatment and Risk for Post-acute Sequelae of COVID-19 in Older Singaporeans: Author's Response." Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 31, no. 1 (2025): 139. https://doi.org/10.1016/j.cmi.2024.10.002.
MLA (9th ed.) CitationLE, Wee, et al. "Nirmatrelvir/ritonavir Treatment and Risk for Post-acute Sequelae of COVID-19 in Older Singaporeans: Author's Response." Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 31, no. 1, 2025, p. 139, https://doi.org/10.1016/j.cmi.2024.10.002.
